Christopher B. Hopson
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune cells in cancer, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Design of amidobenzimidazole STING receptor agonists with systemic activity(2018)822 cited
- → Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist(2008)282 cited
- → Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist(2005)204 cited
- → Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments(2018)201 cited
- → Hydrazinonaphthalene and Azonaphthalene Thrombopoietin Mimics Are Nonpeptidyl Promoters of Megakaryocytopoiesis(2001)119 cited
- → Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity(2019)43 cited
- → New benzimidazoles as thrombopoietin receptor agonists(2006)42 cited
- → Characterization of Siglec-5 (CD170) expression and functional activity of anti–Siglec-5 antibodies on human phagocytes(2003)37 cited
- → Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.(2004)32 cited
- → PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY(2019)17 cited